Stocksigma LogoStocksigma Logo

Tavexia Lifecare Explores 60% Stake Acquisition in Meyonex Pharmaceuticals and Appoints Auditor

Tavexia Lifecare's board approved evaluating an acquisition of up to a 60% equity stake in unlisted Meyonex Pharmaceuticals (paid-up capital of ₹13.998

Tavexia Lifecare Explores 60% Stake Acquisition in Meyonex Pharmaceuticals and Appoints Auditor

Sattva Sukun Lifecare Ltd · Others (Uncategorized) · 08 Sept 2026, 12:58 am

Tavexia Lifecare Explores 60% Stake Acquisition in Meyonex Pharmaceuticals and Appoints Auditor Tavexia Lifecare's board approved evaluating an acquisition of up to a 60% equity stake in unlisted Meyonex Pharmaceuticals (paid-up capital of ₹13.998 crore), authorizing directors to conduct due diligence, valuations, and negotiations. Effective 7th Sep'26, the board accepted the resignation of statutory auditor M/s SSRV & Associates and approved appointing M/s DEVAM & Associates LLP for a five-year term (FY27 to FY31), pending shareholder approval. Additionally, the board approved the re-appointment of Independent Director Khushboo Vasudev for a second five-year term starting 31st Dec'26.

Original exchange filing (PDF)

More announcements from Sattva Sukun Lifecare Ltd

All Sattva Sukun Lifecare Ltd announcements